Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y6G5
UPID:
COMDA_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y6G5; D3DT07; Q9P077
Background:
COMM domain-containing protein 10 plays a crucial role in cellular processes by modulating the activity of cullin-RING E3 ubiquitin ligase complexes, as evidenced by research findings (PubMed:21778237). Additionally, it has been shown to down-regulate the activation of NF-kappa-B, a key factor in immune and inflammatory responses (PubMed:15799966).
Therapeutic significance:
Understanding the role of COMM domain-containing protein 10 could open doors to potential therapeutic strategies.